Supera Peripheral Stent System
Abbott Vascular (Idef Technologies Inc) · Decision date Nov 6, 2026
What did the FDA approve?
The FDA recorded an approval decision on 2026-11-06 for P120020/S037, a Special (Immediate Track) supplement to the Supera Peripheral Stent System premarket approval held by Abbott Vascular (Idef Technologies Inc). The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename. The recorded scope is limited to revisions of the Instructions for Use and patient guide that modify warnings, precautions and contraindications, plus the magnetic resonance imaging labeling.
This action amends labeling for an already-approved stent system; it is not a new approval of the device itself. The source record does not state which warnings, precautions, contraindications or MRI labeling text changed, nor does it include the revised documents, so the substance of the revisions remains unknown. No clinical, efficacy or patient-selection conclusions follow from this entry.
The device category is recorded as a stent for the superficial femoral artery, with product code NIP and Cardiovascular specialty. The source data do not describe components, materials or delivery system details.
FDA approval order statement
Approval for revisions to the Instructions for Use and patient guide to modify warnings, precautions and contraindications, and the magnetic resonance imaging labeling
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 6, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120020/S037
- Regulatory pathway
- PMA supplement
- Product code
- NIP
- Decision code
- APPR
- Decision date
- Nov 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Product code
- NIP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P120020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120020 · Original PMA
SUPERA PERIPHERAL STENT SYSTEM
P120020/S037 received
Application receipt date recorded by FDA.
P120020/S037 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P120020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular (Idef Technologies Inc) | PMA approval | Mar 28, 2014 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Vascular (Idef Technologies Inc)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P120020/S037
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


